… will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® … will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® … ). As scientists we use this time at conferences to meet research colleagues, other companies, and academics to share …
… technology was introduced at the Company’s second annual Research & Development Investor Day and in vivo proof of … F508del mutation were presented at the North American CF conference. A Phase 2 study is currently being designed and … QR-313 pre-clinical data were presented at the EB2017 ResearchConference and ESDR meeting. IND-enabling studies …
